Corbus Pharmaceuticals Holdings (Nasdaq:CRBP) - Hisse Senedi Fiyatı, Haberler ve Analizler

CRBP Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Corbus Pharmaceuticals Holdings, Inc. ciddi hastalıkları yenmek için ürünler geliştirmektedir.

Şirket hakkında

CRBP temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Revenue is forecast to grow 75.49% per year

Earnings have grown 18.5% per year over the past 5 years

Risk Analizi

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 29.2% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the US market

+ 1 daha fazla risk

Corbus Pharmaceuticals Holdings, Inc. Rakipler

Acumen Pharmaceuticals

NasdaqGS:ABOS

US$170.9m

Instil Bio

NasdaqCM:TIL

US$187.2m

Design Therapeutics

NasdaqGS:DSGN

US$294.4m

Verastem

NasdaqCM:VSTM

US$157.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Corbus Pharmaceuticals Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$16.92
52 Haftanın En Yüksek Seviyesi	US$61.90
52 Haftanın En Düşük Seviyesi	US$3.03
Beta	2.53
11 Aylık Değişim	-11.92%
3 Aylık Değişim	-68.04%
1 Yıllık Değişim	235.71%
33 Yıllık Değişim	-48.26%
5 Yıllık Değişim	-87.21%
Halka arzdan bu yana değişim	-81.20%

Son Haberler & Güncellemeler

Recent updates

Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Jun 12

Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

May 14

What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Mar 11

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

Feb 04

Corbus Pharmaceuticals: Down But Not Out

Jan 29

Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?

Jan 09

Corbus's lenabasum shows benefit in autoimmune disorder

Nov 09

Hissedar Getirileri

	CRBP	US Biotechs	US Pazar
7D	3.5%	-0.7%	-1.6%
1Y	235.7%	19.8%	30.8%

Getiri vs. Endüstri: CRBP exceeded the US Biotechs industry which returned 19.8% over the past year.

Getiri vs Piyasa: CRBP exceeded the US Market which returned 30.8% over the past year.

Fiyat Oynaklığı

Is CRBP's price volatile compared to industry and market?
CRBP volatility
CRBP Average Weekly Movement	20.5%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: CRBP's share price has been volatile over the past 3 months compared to the US market.

Zaman İçindeki Volatilite: CRBP's weekly volatility has decreased from 40% to 20% over the past year, but is still higher than 75% of US stocks.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	19	Yuval Cohen	www.corbuspharma.com

Bir biyofarmasötik şirketi olan Corbus Pharmaceuticals Holdings, Inc. ciddi hastalıkları yenmek için ürünler geliştirmektedir. Faz I klinik denemesinde olan monometil auristatin E'nin (MMAE) sitotoksik bir yükünü serbest bırakmak için kanser hücrelerinde Nectin-4 ekspresyonunu hedefleyen bir antikor ilaç konjugatı (ADC) olan CRB-701'i geliştirmektedir; CRB-601, solid tümörlerin tedavisi için kanser hücrelerinde eksprese edilen TGFß aktivasyonunu bloke eden bir anti-integrin monoklonal antikor; CRB-913, obezite tedavisi için periferal olarak kısıtlanmış bir kannabinoid tip-1 (CB1) reseptör ters agonisti. Jenrin Discovery, LLC ile yaklaşık 600 bileşikten oluşan Jenrin kütüphanesi ve birden fazla yayınlanmış ve bekleyen patent başvurusu da dahil olmak üzere lisanslı ürünleri geliştirmek ve ticarileştirmek için bir lisans anlaşması vardır.

Corbus Pharmaceuticals Holdings, Inc. Temel Bilgiler Özeti

Corbus Pharmaceuticals Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CRBP temel i̇stati̇sti̇kler
Piyasa değeri	US$203.78m
Kazançlar(TTM)	-US$34.97m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-5.8x

F/K Oranı

CRBP aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CRBP gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$26.16m
Brüt Kâr	-US$26.16m
Diğer Giderler	US$8.81m
Kazançlar	-US$34.97m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.90
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	8.6%

CRBP uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CRBP Stoklara Genel Bakış

Ödüller

Risk Analizi

Corbus Pharmaceuticals Holdings, Inc. Rakipler

NasdaqGS:ABOS

US$170.9m

NasdaqCM:TIL

US$187.2m

NasdaqGS:DSGN

US$294.4m

NasdaqCM:VSTM

US$157.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Price target decreased by 13% to US$71.00

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Recent updates

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Price target decreased by 13% to US$71.00

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering.

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

New minor risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

New minor risk - Shareholder dilution

Price target increased to US$2.20

Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors

First half 2022 earnings released

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Price target increased to US$2.20

Corbus Pharmaceuticals Holdings, Inc. Enters into a Binding Term Sheet with Venn Therapeutics, LLC, to Resolve the Claims by Venn Against the Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$1.65

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020)

Head of Research & Chief Medical Officer Barbara White has left the company

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020)

Consensus revenue estimates fall to US$2.32m

Corbus Pharmaceuticals Holdings, Inc.(NasdaqGM:CRBP) dropped from Russell 3000E Growth Index

Corbus Pharmaceuticals Announces Topline Results from Determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Corbus Pharmaceuticals Holdings, Inc. Announces Licensing Deals for Two New Monoclonal Antibodies, CRB-601 and CRB-602 to Further Expand Pipeline into Cancer and Fibrotic Diseases

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.43 loss in 1Q 2020)

Consensus revenue estimates increase to US$3.68m

Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

Consensus forecasts updated

Full year 2020 earnings released: US$1.42 loss per share (vs US$1.12 loss in FY 2019)

Corbus Pharmaceuticals Holdings, Inc. Provides Clinical Program Updates

What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Corbus Pharmaceuticals Holdings, Inc. to Report Q4, 2020 Results on Mar 15, 2021

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

New 90-day high: US$2.58

Corbus Pharmaceuticals: Down But Not Out